Whole genome sequence analysis of apparent treatment resistant hypertension status in participants from the Trans-Omics for Precision Medicine program
- PMID: 38162683
- PMCID: PMC10755672
- DOI: 10.3389/fgene.2023.1278215
Whole genome sequence analysis of apparent treatment resistant hypertension status in participants from the Trans-Omics for Precision Medicine program
Abstract
Introduction: Apparent treatment-resistant hypertension (aTRH) is characterized by the use of four or more antihypertensive (AHT) classes to achieve blood pressure (BP) control. In the current study, we conducted single-variant and gene-based analyses of aTRH among individuals from 12 Trans-Omics for Precision Medicine cohorts with whole-genome sequencing data. Methods: Cases were defined as individuals treated for hypertension (HTN) taking three different AHT classes, with average systolic BP ≥ 140 or diastolic BP ≥ 90 mmHg, or four or more medications regardless of BP (n = 1,705). A normotensive control group was defined as individuals with BP < 140/90 mmHg (n = 22,079), not on AHT medication. A second control group comprised individuals who were treatment responsive on one AHT medication with BP < 140/ 90 mmHg (n = 5,424). Logistic regression with kinship adjustment using the Scalable and Accurate Implementation of Generalized mixed models (SAIGE) was performed, adjusting for age, sex, and genetic ancestry. We assessed variants using SKAT-O in rare-variant analyses. Single-variant and gene-based tests were conducted in a pooled multi-ethnicity stratum, as well as self-reported ethnic/racial strata (European and African American). Results: One variant in the known HTN locus, KCNK3, was a top finding in the multi-ethnic analysis (p = 8.23E-07) for the normotensive control group [rs12476527, odds ratio (95% confidence interval) = 0.80 (0.74-0.88)]. This variant was replicated in the Vanderbilt University Medical Center's DNA repository data. Aggregate gene-based signals included the genes AGTPBP, MYL4, PDCD4, BBS9, ERG, and IER3. Discussion: Additional work validating these loci in larger, more diverse populations, is warranted to determine whether these regions influence the pathobiology of aTRH.
Keywords: TOPMed; antihypertensive response; blood pressure; treatment resistant hypertension; whole genome sequencing.
Copyright © 2023 Armstrong, Srinivasasainagendra, Ammous, Assimes, Beitelshees, Brody, Cade, Ida Chen, Chen, de Vries, Floyd, Franceschini, Guo, Hellwege, House, Hwu, Kardia, Lange, Lange, McDonough, Montasser, O’Connell, Shuey, Sun, Tanner, Wang, Zhao, Carson, Edwards, Kelly, Kenny, Kooperberg, Loos, Morrison, Motsinger-Reif, Psaty, Rao, Redline, Rich, Rotter, Smith, Smith, Irvin and Arnett.
Conflict of interest statement
BP serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson and Johnson. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
References
-
- Akinyelure O. P., Sakhuja S., Colvin C. L., Clark D., 3rd, Jaeger B. C., Hardy S. T., et al. (2020). Cardiovascular health and transition from controlled blood pressure to apparent treatment resistant hypertension: the Jackson heart study and the REGARDS study. Hypertension 76 (6), 1953–1961. 10.1161/HYPERTENSIONAHA.120.15890 - DOI - PubMed
Grants and funding
- HHSN268201100037C/HL/NHLBI NIH HHS/United States
- R01 HL092577/HL/NHLBI NIH HHS/United States
- U54 HG003273/HG/NHGRI NIH HHS/United States
- T32 HL007457/HL/NHLBI NIH HHS/United States
- R01 HL105756/HL/NHLBI NIH HHS/United States
- HHSN268201800001C/HL/NHLBI NIH HHS/United States
- R01 MD012765/MD/NIMHD NIH HHS/United States
- R01 HL117626/HL/NHLBI NIH HHS/United States
- R01 HL055673/HL/NHLBI NIH HHS/United States
- K01 HL135405/HL/NHLBI NIH HHS/United States
- F31 DK108444/DK/NIDDK NIH HHS/United States
- R01 HL120393/HL/NHLBI NIH HHS/United States
- R01 HL046380/HL/NHLBI NIH HHS/United States
- U54 HG003067/HG/NHGRI NIH HHS/United States
- R01 HL121007/HL/NHLBI NIH HHS/United States
- R01 HL111249/HL/NHLBI NIH HHS/United States
- HHSN268201600032C/ES/NIEHS NIH HHS/United States
- U19 CA203654/CA/NCI NIH HHS/United States
- U01 HL120393/HL/NHLBI NIH HHS/United States
- R01 HL113338/HL/NHLBI NIH HHS/United States
- R01 DK117445/DK/NIDDK NIH HHS/United States
- R01 HL153805/HL/NHLBI NIH HHS/United States
- R35 HL135818/HL/NHLBI NIH HHS/United States
- R01 HL098433/HL/NHLBI NIH HHS/United States
- HHSN268201500015C/HL/NHLBI NIH HHS/United States
- HHSN268201600033C/ES/NIEHS NIH HHS/United States
- HHSN268201500014C/HL/NHLBI NIH HHS/United States
- K12 HD043483/HD/NICHD NIH HHS/United States
